- Providers
- Life Sciences
- Conference
ASCO® Annual Meeting 2022
Tempus’ mission is to apply data and AI to diagnostics in order to route every patient to a personalized, optimal therapeutic path. We’re helping treat the patients of today while finding cures for the patients of tomorrow. We are pleased to share our latest scientific and clinical research findings during the 2022 ASCO® Annual Meeting.
Precision Oncology Now: Enhancing patient care with integrated clinical applications that are powered by multimodal data
Learn to empower your practice and research program through Tempus’ comprehensive portfolio of NGS offerings. Discover how one of the world’s largest cancer platforms accelerates discovery, provides personalized treatment options, and precisely matches patients to clinical trials.
Join the Tempus team at booth #5063 directly following the session for a live Q&A with the presenters, Dr. James Chen and Dr. Calvin Chao.
Genetic ancestry differences in tumor mutation and expression in early and average onset colorectal cancer
Used genetic ancestry instead of race/ethnicity classes to provide a more quantitative and precise profile of shared genetic background that can underlie biological race differences in cancer etiology and outcomes
First Author Nina Sanford; UTSW
Learn more↗Paired tumor/normal sequencing reduces apparent racial differences in tumor mutational burden (TMB)
The use of xT tumor/normal match reduced apparent discrepancy in TMB levels between racial groups, particularly for Black and Asian patients
First Author Christopher W. Seder; Rush University
Learn more↗Real world data enables large-scale assessment of WHO CNS5 glioma classification
Researchers analyzed a de-identified dataset of CNS tumors and found that reclassifying according to the new WHO classification system resulted in more accurate prognostic stratification than the original diagnosis
Robin Buerki; Northwestern
Learn more↗Dual tissue and plasma testing improves detection of actionable variants in patients with solid cancers
Performing liquid biopsy in addition to tissue based testing identifies more patients with clinically actionable variants
Wade Iams; Vanderbilt
Learn more↗Operational Metrics for the ELAINE II study Combining a Traditional Approach with a Just-in-Time Model
By combining TIME trial and traditional enrollment models clinical trials may recruit more patients and reach full enrollment faster
Sibel Blau; Northwestern Medical
Learn more↗Clinical RNA-sequencing improves the detection of actionable fusions over DNA-sequencing alone
In the largest fusion analysis of its kind Tempus reviewed a real-world data set of 77,400 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing; The inclusion of RNA sequencing improves fusion detection vs DNA alone
Lead Author Jack Michuda; Tempus Labs
Learn more↗Comparative Analysis of the Targetable Landscape in KRAS-mutated and wild-type Pancreatic Adenocarcinoma
Todd Knepper; Moffitt, Prateek Gulhati; Rutgers
Learn more↗Natural Language Processing-Optimized Case Selection for RWE Studies
Jacob Koskimaki; Astrazeneca
Learn more↗Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E–mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immuno-metabolomic biomarkers
Mohamed E. Salem; Levine Cancer Institute
Learn more↗Genomic landscape of SMARCA4-deficient lung tumors by clinical RNA sequencing
Brian Pham; UC Davis
Learn more↗Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) colorectal cancer (CRC)
Mohamed E. Salem; Levine Cancer Institute
Learn more↗Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms.
Sukhmani Kaur Padda; Cedars Sinai
Learn more↗An analysis of EHR records to determine treatment patterns of women with advanced TNBC
Alexander Liede; University of Chicago
Schedule a meeting with us
We'll be in touch shortly.